Biosimilar Retacrit® in the Treatment of Chemotherapy-induced Anaemia in Oncology and Haematology (SYNERGY)

Hospira

Status: Completed

Conditions: Chemotherapy-induced Anemia

Study type: Observational

Funder types: Industry

Identifiers

NCT02158169

Synergy

Details and patient eligibility

About

The aim of this study is to describe, in a real-life context, the impact of an epoetin alpha biosimilar, Retacrit®, on anaemia in patients receiving chemotherapy, according to concomitant iron supplementation.

Full description

This is a longitudinal, observational, prospective, multicentre, cohort study, conducted on a representative sample of public and/or private hospital-based oncologists and haematologists practicing in Metropolitan France.

Enrollment: 2,167 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, aged 18 years and older, seen by the oncologist or hematologist for chemotherapy.
• Patients for whom the oncologist or hematologist has decided the initiation of an epoetin alpha biosimilar treatment (Retacrit®) for anemia.
• Patients informed about the computer processing of their medical data and their right of access and correction.

Exclusion criteria

• Patients with hemoglobin concentrations >11 g/dL.
• Patients who have been transfused within the previous month.
• Patients who are hypersensitive to erythropoietin or one of its excipients.
• Patients participating or having participated in the previous month in a clinical trial in the field of anaemia in oncology.
• Patients refusing to participate in the observational study.